Cormorant Asset Management ARQT Position
Exited5-Fund ConvergenceCormorant Asset Management exited their position in Arcus Biosciences Inc. (ARQT) in Q3 2023, after holding the stock for 2 quarters.
The position was first reported in Q2 2023 and has been tracked across 2 quarterly 13F filings.
ARQT is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Domvanalimab in 77 days (Jun 30, 2026), making the timing of Cormorant's position particularly relevant.
Short interest stands at 15.6% of float with 11.3 days to cover, indicating significant bearish positioning against the stock.
About Arcus Biosciences Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Full company profile →Short Interest
15.6%
11.3 days to cover
Cormorant Asset Management ARQT Position History
Frequently Asked Questions
Does Cormorant Asset Management own ARQT?
No. Cormorant Asset Management exited their position in Arcus Biosciences Inc. (ARQT) in Q3 2023. They previously held the stock for 2 quarters.
How many hedge funds own ARQT?
5 specialist biotech hedge funds currently hold ARQT, including Driehaus Capital, OrbiMed Advisors, Perceptive Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy ARQT?
Cormorant Asset Management's position in ARQT was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's ARQT position increasing or decreasing?
Cormorant Asset Management completely exited their ARQT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARQTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →